AVEVA Group Expects Revenue Growth To Be Lower In FY23 Than In FY22

AVEVA Group plc (AVV.L), on Wednesday, issued trading update for the financial year ended 31 March 2022, and reported 18% revenue growth in the fourth quarter on a pro forma organic constant currency basis, driven by a very good performance from PI System. This resulted in overall Group revenue growth on the same basis for FY22 of 7%, again with a strong contribution from PI System.

The Group expects adjusted EBIT margin to be consistent with the previous year pro forma results at just below 30%.

ARR increased by 9%, largely driven by the heritage AVEVA business, which grew ARR significantly ahead of revenue.

For fiscal 2023, revenue growth is expected to be lower than in FY22 and adjusted EBIT margin is expected to reduce, before resuming growth in FY24. Cash conversion is expected to significantly improve in FY23 and beyond.

Also, AVEVA reconfirmed its previously announced financial targets for the five financial years ending 31 March 2026.

The company continues to expect a revenue Compound Annual Growth Rate or CAGR of around 10% between FY21 and FY26, on a constant currency basis, supported by revenue synergies relating to the OSIsoft acquisition, which are expected to be at least $100 million in FY26.

In addition, AVEVA still expects recurring revenue at over 80% of total revenue in FY26 driven by a continued transition to Subscription and the accelerated adoption of Cloud by customers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT